Last reviewed · How we verify
TRIHEPTANOIN
At a glance
| Generic name | TRIHEPTANOIN |
|---|---|
| Drug class | Medium-chain Triglyceride [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 2020 |
Approved indications
Common side effects
- Abdominal pain
- Diarrhea
- Vomiting
- Nausea
Key clinical trials
- Proof of Concept of an Anaplerotic Study Using Brain Phosphorus Magnetic Resonance Spectroscopy in Huntington Disease (PHASE2)
- Long-Chain Fatty Acid Oxidation Disorders In-Clinic Disease Monitoring Program
- Study to Evaluate the Use of Triheptanoin in Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD) (PHASE2)
- Triheptanoin for Children With Primary-Specific Pyruvate Dehydrogenase Complex (PDC) Deficiency (PHASE1)
- A Study to Determine the Effect of Triheptanoin Compared With Even-Chain MCT on MCEs in Pediatric Patients With LC-FAOD (PHASE3)
- Expanded Access to Triheptanoin
- Pilot Study, Comparative, Single-center, Randomized, Crossover, Double-blind, Against Placebo, Testing the Effectiveness of Triheptanoin Oil in Alternating Hemiplegia of Childhood (PHASE2)
- Phase II Open Label Study Using Triheptanoin in Patients With Glucose Type 1 Transporter Deficiency GLUT1-DS (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TRIHEPTANOIN CI brief — competitive landscape report
- TRIHEPTANOIN updates RSS · CI watch RSS